Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Should l Buy ?
Clinical Trial Update: Vigil Neuroscience reported on the Phase 2 IGNITE trial of iluzanebart, a TREM2 agonist for treating adult-onset leukoencephalopathy, showing favorable safety but no efficacy in ALSP patients.
Study Discontinuation: Due to the lack of beneficial effects on biomarkers or clinical endpoints, the long-term extension study of the Phase 2 trial will be discontinued.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
